# ABBOTT LABORATORIES (ABT) · Edgar & Edgarette company card

> Abbott Laboratories (ABT) grew revenue 5.7% in FY2025 to $44.3 billion, operating margin 18.2% against a -3.8% median for pharmaceutical preparations, equity 60.1% of assets, and dividend per share up 3 years running. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1800 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ABT) · [JSON](https://www.pops4.com/boards/company/ABT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $44.3B |
| Revenue growth, 1 year | 5.7% |
| Revenue growth per year | 0.7% |
| Operating margin | 18.2% (prior year 16.3%) |
| Net margin | 14.7% |
| Operating cash flow | $9.6B |
| Capital spending | $2.2B |
| Free cash flow | $7.4B |
| Cash | $8.5B |
| Long-term debt | $12.9B |
| Total assets | $86.7B |
| Total equity | $52.1B |
| Equity ÷ assets | 60.1% |
| Return on equity | 12.5% |
| Dividend per share | $2.4 |
| Dividend years rising | 3 |

## Readings, computed from those figures

- Altman Z: 4.8 (safe zone)
- Piotroski F: 6 of 9 (solid)
- Beneish M: -2.51 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow now · steady, with strong cash arriving today

## Edgarette's reading

Exposure: revenue $44.3B (FY2025), total debt $12.9B. Experience: revenue up 5.7% on the year, up 0.7% a year over 4 years; operating margin 18.2%, up from 16.3%. Soundness: equity 60.1% of assets, return on equity 12.5%, payout 63.1% of profit, dividend per share up 3 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $40.4B and $48.3B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $37.4B to $51.8B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 18.2% against a -3.8% median; growth 5.7% against 13.7%.

Range logged 2026-09-26, receipt 31e3f99612fb725e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-04-27 ([filing](https://www.sec.gov/Archives/edgar/data/1800/000110465926049434/0001104659-26-049434-index.htm))

## Recent filings

- 10-Q · filed 2026-11-04 · [filing](https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm)
- 8-K · filed 2026-10-21 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1800/000110465926117587/0001104659-26-117587-index.htm)
- 8-K · filed 2026-10-21 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1800/000162828026066601/0001628280-26-066601-index.htm)
- 8-K · filed 2026-08-20 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1800/000110465926099247/0001104659-26-099247-index.htm)
- 10-Q · filed 2026-07-28 · [filing](https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm)
- 8-K · filed 2026-07-16 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1800/000162828026048377/0001628280-26-048377-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000001800.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1800

## Cite

POPS4, Edgar & Edgarette: ABBOTT LABORATORIES (ABT) company card, from the company's own SEC filings, accessed 2026-11-10, https://www.pops4.com/boards/company/ABT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.